HOME >> BIOLOGY >> NEWS
LA BioMed Medical/Research Briefs, July/August 2004

  • LA BioMed Supports Stem Cell Initiative
  • Ethnic Breast Cancer?
  • A Periodic Table For Biology

    La BioMed Supports Stem Cell Initiative

    In coalition with major health and business groups throughout California, LA BioMed has indicated its support for the California Stem Cell Bond Issue Initiative that recently qualified for November's ballot. The initiative will allocate money from a $3 billion bond to fund promising, California-based stem cell research.

    The initiative will distribute an average of $295 million per year over a 10-year period to fund stem cell research at California's universities and other advanced medical research facilities. It will fund all aspects of stem cell therapy development from basic research through clinical trials to the actual delivery of therapies to patients.

    Kenneth P. Trevett, President and CEO of LA BioMed, recently issued the following statement about the initiative:

    The stem cell initiative is a necessary step in the pursuit of scientific research because federal funding for stem cell research has been limited. Unquestionably, stem cell therapy is potentially the most important medical advance since the discovery of antibiotics. This critically important statewide initiative closes the federal funding gap and sets a new state model for advancing scientific research. From an economic standpoint, California will benefit from patents and royalties that result from the research. Construction of research facilities and new research jobs will generate millions of dollars in new tax revenues for California. More importantly, if stem cell research results in a single cure that reduces healthcare costs by just one percent, it would pay for itself several times over during the following decade and save lives along the way.

    Mr. Trevett is available to speak the merits of the stem cell initiative. To contact him, telephone or e-mail the Communicatio
    '"/>



  • Contact: David Feuerherd
    df@issuesmanagement.com
    310-215-0234
    Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
    30-Jul-2004


    Page: 1 2 3

    Related biology news :

    1. BioMed Central to consult funders and librarians over Open Access payment model
    2. BioMed Central explodes Open Access myths
    3. The Scientist and BioMed Central come together to publish high-impact magazine
    4. BioMed Central is pleased to announce the publication of Sydney Brenners autobiography
    5. BioMed Central to deposit e-journals with the British Library
    6. BioMed Central to consider charging authors for paper submissions
    7. Get Research on the move with BioMed Central
    8. BioMed Central to launch at microbiology meeting
    9. BioMed Central to free scientists and clinical researchers from copyright restrictions

    Post Your Comments:
    *Name:
    *Comment:
    *Email:


    (Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
    (Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
    (Date:1/30/2017)...   Invitae Corporation (NYSE: NVTA ... today announced that it will report its fourth quarter ... on Monday, February 13, 2017, and Invitae,s management team ... p.m. Eastern / 1:45 p.m. Pacific. ... financial results, guidance, and recent developments and will spend ...
    Breaking Biology News(10 mins):
    (Date:2/27/2017)... and HAMILTON, Bermuda , Feb. ... ADXS ) and SELLAS Life ... on developing cancer immunotherapies, today announced that Advaxis ... novel cancer immunotherapy agent using Advaxis, proprietary ... WT1 targeted heteroclitic peptide antigen mixture (galinpepimut-S). ...
    (Date:2/25/2017)... (PRWEB) , ... February 25, 2017 , ... ... Verified Clinical Trials in an ongoing effort to create meaningful change ... advocacy, and pharmaceutical research with emphasis on consumers and patients’ mental health well-being. ...
    (Date:2/24/2017)...  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... and CEO, Jim Joyce . In ... Saturday, Bill Gates warned world leaders that ... nuclear weapons. Mr. Gates expressed his concern, which is ... scientific terrorists have access to the necessary tools to ...
    (Date:2/24/2017)... 2017 China Biologic Products, Inc. (NASDAQ: CBPO) ("China ... company in China, today announced its financial results for the ... Fourth Quarter 2016 Financial Highlights Total ... in RMB terms, or increased by 13.6% in USD terms ... of 2015. Gross profit increased by 13.3% ...
    Breaking Biology Technology:
    Cached News: